By SquaredTown on July 30, 2025
Potential Best-in-Class TEAD Autopalmitoylation Inhibitor Supported by Promising Clinical Data SAN MATEO, Calif., July 30, 2025 /PRNewswire/ -- Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class cancer therapies targeting the Hippo...